电邮这篇文章 CURRENT ANTI-INFLAMMATORY TREATMENT IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- 作者: Shmelev EI1, Shmeleva NM1
-
隶属关系:
- Central Research Institute of Tuberculosis
- 期: 卷 84, 编号 6 (2012)
- 页面: 73-76
- 栏目: Editorial
- URL: https://bakhtiniada.ru/0040-3660/article/view/31083
- ID: 31083
如何引用文章
全文:
详细
The lecture analyses current tools of anti-inflammatory treatment of patients with chronic obstructive pulmonary disease (COPD). Anti-inflammatory treatment is aimed at a key element of COPD pathogenesis. The results of treatment with main anti-inflammatory drugs and methods in COPD management are reviewed as well as efficacy of a new anti-inflammatory drug roflumilast in COPD patients.
作者简介
E Shmelev
Central Research Institute of Tuberculosis
Email: eishmelev@mail.ru
д-р мед. наук, проф., рук. отд. пульмонологии Moscow
N Shmeleva
Central Research Institute of Tuberculosis
Email: eishmelev@mail.ru
канд. мед. наук, ст. науч. сотр. отд. пульмонологии; окружной пульмонолог САО Moscow
参考
- Blamoun A., Batty G., DeBari V. et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: Evidence from a retrospective cohort study. Int. J. Clin. Pract. 2008; 62 (9): 1373—1378.
- Grootendorst D., Gauw S., Verhoosel R. et al. Reduction in sputum neutrophils and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62: 1081—1087.
- Rabe K., Bateman E., O’Donnell D. et al. Roflumilast — an oral antiinflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366: 563—571.
- Calverley P., Sanchez-Toril F., McIvor A. et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 176: 154—161.
- Martinez F., Calverley P., Goehring U. et al. Defining patient populations in COPD: Experience with roflumilast. COPD7 2010; poster 12. Available at: www.copdconferences.org
- Bateman E., Calverley P., Fabbri L. et al. Efficacy of roflumilast in patients with a history of frequent exacerbations: Pooled data from pivotal 12-month studies. Eur Respir J. 2010; 36: P4003.
- Calverley P., Rabe K., Goehring U. et al. Roflumilast in symptomatic chronic obstructive disease: two randomised clinical trials. Lancet 2009; 374: 685—694.
- Fabbri L., Calverley P., Izquierdo-Alonso J. et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695—703.
- Martinez F., Calverley P., Goehring U. et al. Defining patient populations in COPD: Experience with roflumilast. COPD7 2010; poster 12. Available at: www.copdconferences.org
- Calverley P., Rabe K., Goehring U. et al. Roflumilast in symptomatic chronic obstructive disease: two randomised clinical trials. Lancet 2009; 374: 685—694.
- Martinez F., Rabe K., Wouters E. et al. Time course and reversibility of weight decrease with roflumilast, a phosphodiesterase inhibitor. Am. J. Respir. Crit. Care Med. 2010; 181: A4441.
补充文件
